Vaxart (VXRT) Scheduled to Post Earnings on Wednesday

Vaxart (NASDAQ:VXRT - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Vaxart had a negative return on equity of 114.19% and a negative net margin of 543.21%. The business had revenue of $6.40 million during the quarter, compared to the consensus estimate of $65.70 million. During the same quarter last year, the company earned ($0.16) earnings per share. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Price Performance

Shares of Vaxart stock traded down $0.04 during trading hours on Friday, hitting $0.69. The company's stock had a trading volume of 1,520,029 shares, compared to its average volume of 2,502,463. Vaxart has a 12 month low of $0.52 and a 12 month high of $1.54. The stock has a 50 day moving average of $0.83 and a 200 day moving average of $0.77. The company has a market capitalization of $121.63 million, a PE ratio of -1.57 and a beta of 0.70.

Analysts Set New Price Targets

Separately, Oppenheimer began coverage on Vaxart in a research report on Thursday, August 15th. They set an "outperform" rating and a $4.00 price objective for the company.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.